Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: SOD2

Summary for SOD2

Gene information	Gene symbol	SOD2
	Ensembl ID	ENSG00000291237
	Entrez ID	6648
	Gene name	superoxide dismutase 2
	Synonyms	GC1\|GClnc1\|IPOB\|MnSOD
	Gene type	protein_coding
	UniProtAcc	P04179

Top

Dataset with differentially expressed gene: SOD2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	0.560721	1.42e-40
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.938832	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	0.480832	1.19e-08
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.404203	6.55e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.308925	1.32e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.46854	2.78e-21
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.261439	5.60e-19
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.21794	2.04e-19
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.909415	9.84e-42
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.543378	4.48e-23
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-1.12069	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.301152	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.497771	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.565144	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-1.1087	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.824089	0.00e+00
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-1.16358	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	1.104	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.274663	0.00e+00

Top

Expression of SOD2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to SOD2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Gene symbol	Mechanism
SOD2	Drug Inactivation by Structure Modification
SOD2	Unusual Activation of Pro-survival Pathway

Page: 1

Top

MicroRNAs (miRNA) regulating SOD2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
SOD2	hsa-miR-8069	97.0521	NM_001322815
SOD2	hsa-miR-4482-3p	96.8796	NM_001322815
SOD2	hsa-miR-377-3p	96.1041	NM_001322815
SOD2	hsa-miR-642a-3p	95.1432	NM_001322815
SOD2	hsa-miR-642b-3p	95.1432	NM_001322815
SOD2	hsa-miR-212-3p	94.7681	NM_001322815
SOD2	hsa-miR-132-3p	94.7681	NM_001322815
SOD2	hsa-miR-589-3p	91.0489	NM_001322815
SOD2	hsa-miR-9851-5p	90.7663	NM_001322816
SOD2	hsa-miR-7159-3p	90.3665	NM_001322815
SOD2	hsa-miR-1283	89.6164	NM_000636
SOD2	hsa-miR-382-5p	88.9017	NM_001322815
SOD2	hsa-miR-5193	88.5403	NM_001322816
SOD2	hsa-miR-4477b	88.003	NM_001322816
SOD2	hsa-miR-4705	87.2984	NM_001322815
SOD2	hsa-miR-12130	85.9317	NM_001322816
SOD2	hsa-miR-653-5p	85.6808	NM_001322816
SOD2	hsa-miR-380-5p	85.6442	NM_001024466
SOD2	hsa-miR-3148	85.6329	NM_000636
SOD2	hsa-miR-7160-5p	84.8598	NM_001322815
SOD2	hsa-miR-223-3p	84.4578	NM_001322816
SOD2	hsa-miR-3613-3p	83.487	NM_001322815
SOD2	hsa-miR-892c-5p	83.1995	NM_001322815
SOD2	hsa-miR-125a-5p	82.9946	NM_001322816
SOD2	hsa-miR-125b-5p	82.9946	NM_001322816
SOD2	hsa-miR-4319	82.9946	NM_001322816
SOD2	hsa-miR-802	82.79	NM_001322815
SOD2	hsa-miR-338-5p	82.7884	NM_001322816
SOD2	hsa-miR-3169	82.4649	NM_001322816
SOD2	hsa-miR-659-5p	82.3163	NM_001024466
SOD2	hsa-miR-106a-3p	82.1022	NM_001322815
SOD2	hsa-miR-519d-5p	80.9773	NM_001322815
SOD2	hsa-miR-1276	80.9155	NM_001322815
SOD2	hsa-miR-450b-5p	80.7004	NM_001322816
SOD2	hsa-miR-30a-3p	80.2552	NM_001024466
SOD2	hsa-miR-30d-3p	80.2552	NM_001024466
SOD2	hsa-miR-30e-3p	80.2552	NM_001024466

Page: 1

Top

Motifs and transcription factors (TFs) regulating SOD2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
SOD2	jaspar__MA1125.1	ZNF384 (directAnnotation).
SOD2	transfac_pro__M01239	RELA (directAnnotation).
SOD2	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
SOD2	metacluster_22.21	NFE2L2 (inferredBy_Orthology).
SOD2	transfac_pro__M05762	ZNF774 (directAnnotation).
SOD2	metacluster_46.4	CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; CEBPG; DBP; DBP; EP300; GATAD2A; HES2 (directAnnotation). CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPA; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPB; CEBPD; CEBPD; CEBPD; CEBPD; CEBPD; CEBPE; CEBPE; CEBPE; CEBPG; CEBPG; HLF; HLF (inferredBy_Orthology).
SOD2	metacluster_22.18	BACH2 (inferredBy_Orthology).
SOD2	transfac_pro__M06388	ZNF677 (directAnnotation).
SOD2	transfac_pro__M05831	ZNF880 (directAnnotation).
SOD2	metacluster_22.11	NFE2 (directAnnotation).
SOD2	taipale_tf_pairs__GCM1_CEBPB_MTRSGGGNNNNNNTTRCGYAAN_CAP	CEBPB; GCM1 (directAnnotation).
SOD2	cisbp__M04023	CREB1 (directAnnotation).
SOD2	tfdimers__MD00031	MYB; ZEB1 (directAnnotation).
SOD2	transfac_pro__M05464	SALL1 (directAnnotation).
SOD2	metacluster_167.7	IRF8 (inferredBy_Orthology).
SOD2	cisbp__M02748	NFATC1 (directAnnotation).
SOD2	yetfasco__TBP-TFIIA-TFIIB_1330	GTF2B; TBPL2 (inferredBy_Orthology).
SOD2	tfdimers__MD00409	ETS1; YY2 (directAnnotation).
SOD2	transfac_pro__M06807	SALL2 (inferredBy_Orthology).
SOD2	metacluster_22.13	MAFK (inferredBy_Orthology).
SOD2	kznf__ZNF584_Imbeault2017_OM_RCADE	ZNF584 (directAnnotation).
SOD2	metacluster_22.29	NFE2 (directAnnotation).
SOD2	homer__ATTGCGCAAC_CEBP	CEBPB (inferredBy_Orthology).
SOD2	metacluster_22.17	NFE2 (directAnnotation).
SOD2	tfdimers__MD00095	ELF1; NEUROD1 (directAnnotation).
SOD2	metacluster_22.25	NFE2L2 (directAnnotation).
SOD2	transfac_pro__M06072	ZNF623 (directAnnotation).
SOD2	transfac_pro__M08190	AR (directAnnotation).
SOD2	kznf__ZNF77_Imbeault2017_OM_MEME	ZNF77 (directAnnotation).
SOD2	kznf__CTCF_Rhee2011.3_ChIP-exo	CTCF (directAnnotation).
SOD2	tfdimers__MD00143	IKZF1; MZF1 (directAnnotation).
SOD2	taipale_tf_pairs__ELK1_FOXI1_RSCGGAANNRTMAAYA_CAP_repr	ELK1; FOXI1 (directAnnotation).
SOD2	kznf__ZNF124_Imbeault2017_RP_RCADE	ZNF124 (directAnnotation).
SOD2	taipale_tf_pairs__ETV2_GSC2_RCCGGANNNNNNNNNTAATCCN_CAP_repr	ETV2; GSC2 (directAnnotation).
SOD2	metacluster_171.1	HSFY1; HSFY2; TEAD1; TEAD1; TEAD3 (directAnnotation).
SOD2	transfac_pro__M00801	ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM (directAnnotation). ATF7-NPFF (inferredBy_Orthology).
SOD2	transfac_public__M00039	CREB1 (directAnnotation).
SOD2	metacluster_111.5	E4F1; E4F1 (directAnnotation).
SOD2	transfac_pro__M04746	E2F1 (directAnnotation).
SOD2	transfac_pro__M00716	ZBTB14 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
SOD2	"3-Fluoro-L-tyrosine"	DB04436	small molecule
SOD2	"Benzylsulfonic acid"	DB03297	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."